$IBRX DrPatrick , the man who invented the standard chemotherapy for pancreatic cancer just walked into one of the most advanced pancreatic cancer research centers in the world.
He wasn't carrying chemo. He was carrying immunotherapy.
And the Health Minister of Portugal was in the building.
PSS developed Abraxane - nab-paclitaxel - a chemotherapy that became a standard of care for pancreatic cancer. He sold the company behind it, Abraxis BioScience, to Celgene for $2.9 billion in 2010.
ANKTIVA already has FDA RMAT (Regenerative Medicine Advanced Therapy) designation for pancreatic cancer - granted February 27, 2025 for the reversal of lymphopenia and treatment of multiply relapsed locally advanced or metastatic pancreatic cancer.
Market Data 
Markets 
AI
